Latest Us Market News

Guzman y Gomez (GYG) has reported a record FY25 with $1.2 billion in network sales and a 152% jump in net profit, underpinned by strong comp sales growth and rapid restaurant expansion. The company also declared its first dividend and outlined ambitious plans for continued growth and margin improvement.

Zip Co Limited’s FY25 results reveal a powerful US market expansion driving a 147% rise in cash earnings and a strategic Nasdaq dual listing consideration.

Zip Co has delivered a standout FY25 with cash earnings soaring 147%, driven by rapid US market expansion. The company is now considering a Nasdaq dual listing to fuel further growth.

Zip Co Limited reported a robust FY25 with revenue up 23.5% to $1.07 billion and cash earnings soaring 147%, driven by strong US market expansion and operational efficiencies.

Atomo Diagnostics reports a significant expansion in its supply agreement with Lumos for the Pascal test cassette, tied to the promising CLIA waiver status of the FebriDx test in the US. This deal could nearly double Atomo’s revenues over the next three years.

Sonic Healthcare has delivered solid FY 2025 results, meeting EBITDA guidance with 5% organic revenue growth and setting the stage for up to 19% EPS growth in FY 2026, driven by strategic acquisitions and operational synergies.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion driven by volume growth and strategic acquisitions, while profits declined amid inflationary pressures. The company declared a final dividend of 6.5 cents per share and maintains zero net debt.

QuickFee Limited reports a robust 25% revenue increase in FY25 alongside a return to profitability, setting a confident earnings guidance for FY26 backed by its expanding Connect platform.

QuickFee Limited posted a 25% increase in revenue to A$25.3 million for FY25, driven by strong growth in both Australia and the US, alongside a positive underlying EBTDA of A$2.4 million before a one-off credit loss provision.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.